Alector (ALEC) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALEC shares.
View ALEC analyst ratings or view top-rated stocks.

6 analysts have issued 12 month price targets for Alector's stock. Their ALEC share price forecasts range from $10.00 to $41.00. On average, they predict the company's stock price to reach $16.43 in the next year. This suggests a possible upside of 130.7% from the stock's current price.
View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts.

Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 22.9% and is now trading at $7.12.
View the best growth stocks for 2023 here.

Alector saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,320,000 shares, an increase of 7.7% from the April 30th total of 5,870,000 shares. Based on an average daily trading volume, of 537,400 shares, the short-interest ratio is presently 11.8 days. Currently, 10.3% of the shares of the company are sold short.
View Alector's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ALEC earnings forecast.

Alector, Inc. (NASDAQ:ALEC) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.20. The company had revenue of $16.55 million for the quarter, compared to analysts' expectations of $9.23 million. Alector had a negative trailing twelve-month return on equity of 57.31% and a negative net margin of 107.05%.

ETFs with the largest weight of Alector (NASDAQ:ALEC) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Global X Aging Population ETF (AGNG), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.10%), FMR LLC (7.66%), State Street Corp (4.28%), Braidwell LP (3.85%), Federated Hermes Inc. (3.30%) and JPMorgan Chase & Co. (2.86%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Richard H Scheller, Robert King, Robert Paul, Shehnaaz Suliman and Terrance Mcguire.
View institutional ownership trends.

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALEC stock can currently be purchased for approximately $7.12.

Alector (NASDAQ:ALEC) has a market capitalization of $593.45 million and generates $133.62 million in revenue each year. The company earns $-133,310,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

The company employs 208 workers across the globe.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.